2017
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andrés V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 2017, 355: 842-847. PMID: 28104796, PMCID: PMC5542057, DOI: 10.1126/science.aag1381.Peer-Reviewed Original ResearchConceptsTET2-deficient cellsLow-density lipoprotein receptor-deficient miceLipoprotein receptor-deficient miceClonal hematopoiesisBlood cellsAtherosclerotic cardiovascular diseaseAtherosclerotic plaque sizeReceptor-deficient miceBone marrow reconstitutionInterleukin-1β secretionMutant blood cellsAtherosclerosis developmentNLRP3 inhibitorAtheroprotective activityCardiovascular diseaseMarrow reconstitutionChimeric micePlaque sizeClonal expansionMiceMarked increaseCausal roleTET2 deficiencySomatic mutationsHematopoietic cells
1994
B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation
Leitenberg D, Rappeport J, Smith B. B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation. American Journal Of Clinical Pathology 1994, 102: 231-236. PMID: 8042594, DOI: 10.1093/ajcp/102.2.231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDB-LymphocytesBlotting, SouthernBone MarrowBone Marrow CellsBone Marrow TransplantationChildChild, PreschoolClone CellsFemaleFlow CytometryFluorescent Antibody TechniqueGene Rearrangement, B-Lymphocyte, Heavy ChainHematopoietic Stem CellsHumansImmunophenotypingInfantKineticsMaleMiddle AgedNeprilysinConceptsBone marrow transplantationMarrow transplantationB cell subsetsBone marrow reconstitutionB cell precursorsSurface antigenic phenotypeImmature B cellsImmunoglobulin gene rearrangementsHumoral immunodeficiencyMonoclonal gammapathyMarrow reconstitutionAntigenic phenotypeB cellsTransplantationGene rearrangementsMarked increaseLeukemia lymphoblastsCellsPatientsGammapathyImmunodeficiencyMarrowCD34ReconstitutionMonths
1988
Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support.
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. JAMA Dermatology 1988, 124: 878-84. PMID: 3288124, DOI: 10.1001/archderm.124.6.878.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportBone marrow supportHigh-dose combinationMarrow supportAgent chemotherapyPhase 2 doseMetastatic malignant melanomaOverall response rateMedian survivalComplete responsePartial responseSurgical resectionAdditional patientsMedian timeResidual tumorTreatment courseMalignant melanomaMarrow reconstitutionChemotherapyToxic reactionsPatientsResponse rateEntire groupMonthsDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply